Servier to buy Day One for $2.5B, gaining rare oncology medicinesnews2026-03-06T15:54:59+00:00March 6th, 2026|Endpoints News|
Pfizer gets obesity drug approval in China shortly after buying local rightsnews2026-03-06T12:29:57+00:00March 6th, 2026|Endpoints News|
Kura says its menin inhibitor is preferred treatment for some payersnews2026-03-05T20:34:01+00:00March 5th, 2026|Endpoints News|
Roche partner Zealand posts Phase 2 data for amylin obesity drugnews2026-03-05T20:19:31+00:00March 5th, 2026|Endpoints News|
New FDA bonus pilot to address ‘workforce challenges’news2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Helus Pharma’s stock slides after psychedelic drug data face questions over dosingnews2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Eli Lilly’s new program aims to boost employer coverage of GLP-1snews2026-03-05T17:02:54+00:00March 5th, 2026|Endpoints News|
BIO chief still backs FDA’s Makary despite ‘head-scratcher’ decisionsnews2026-03-04T15:49:33+00:00March 4th, 2026|Endpoints News|
After years of dispute with FDA, Vanda will get a public hearing for jet lag drugnews2026-03-03T20:21:28+00:00March 3rd, 2026|Endpoints News|
Kyowa Kirin ends OX40 trials after Amgen balked, safety concernnews2026-03-03T20:04:15+00:00March 3rd, 2026|Endpoints News|
